Link to RRI

One of the most important roles for Rowett Research Services is to facilitate the transfer of ideas from the bench to the market place so that the research undertaken in our laboratories can be made available in practical, accessible forms to the consumer.

We recognise that many opportunities coming from the research base are often released to the commercial world before they are sufficiently advanced to be commercial interest. As a result we do not release technologies publicly until we have undertaken extensive internal development. In recent years this has been supported through external schemes such as Scottish Enterprise Proof of Concept (four awards) and SMART (two awards) in addition to using our own reserves. In 2004 in recognition of this commitment we became founding members of the Genomia Seed Fund an OST and European supported early stage investment fund.

The company has been active in helping to develop intellectual property for commercialisation through a number of routes. Since 2000 we have successfully created four new companies with technologies spanning the life science arena. Our activities are not limited to this and a number of our technologies have been licensed to established companies for development or are subject to collaborative development programmes.

In some areas the potential impact of the technology may span a number of sectors or interest groups and we are keen to bring together groups of companies in these situations so that opportunities can be maximised.

Rowett has access to a wide range of public funding initiatives in Scotland, the UK and Europe to help support development of science towards the market place or promote collaborations and our expert team are available to help commercial partners to identify, secure and manage the most appropriate financial support.

Click on the links below to learn more about some of our commercialisation successes and current opportunities for investment or collaboration.

Rowett spinout companies

• Provexis plc
• PyrroNostics Limited
• NovaBiotics Limited
• Antoxis Limited

Recent Licensing

• Diagnostic markers : Quidel Corporation Inc
• Therapeutics: Alizyme plc
• Life Science Development tools: Haptogen limited

Technologies Available :

• Colostrum Derived Growth Factor (CDGF) for improved immune response in infants and infirmed
• Anti Inflammatory compounds derived from microbial origins
• Therapeutic probiotics for management of lower gut disorders
• Feed additives for improved performance and reduced methane emissions in ruminants

Opportunities for collaboration

• Intestinal Health Consortium
• Improved bioavailability of health promoting micronutrients
• Other opportunities

Our work is not restricted to the areas above and not all of our activities are listed. To find out more about the work that we do and to find out opportunities to work with us please contact us.